Welcome to our dedicated page for LENSAR news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on LENSAR stock.
LENSAR, Inc. (LNSR) is at the forefront of next-generation femtosecond laser technology, specializing in refractive cataract surgery. The company's flagship product, the LENSAR Laser System, offers unmatched precision and accuracy, optimizing visual outcomes for cataract patients. This cutting-edge system features the proprietary Augmented Reality™, LENSAR’s advanced 3-D imaging, measurement, and guidance technology. By providing high-resolution ocular images in a single scan, the system ensures precise surgical incisions and treatments, all within a single procedure room.
Unlike other femtosecond cataract lasers, the LENSAR Laser System is specifically built for refractive cataract surgery. Designed from the ground up with the needs of cataract surgeons in mind, the system integrates a suite of proprietary technologies aimed at improving visual outcomes, efficiency, and reproducibility. These technologies include Streamline IV and IntelliAxis, which assist surgeons with imaging, procedure planning, and precision.
At its core, LENSAR, Inc. is a commercial-stage medical device company committed to revolutionizing refractive eye surgery. Their product portfolio extends beyond the laser system to include the associated consumable components, such as the disposable patient interface device (PID) kits and procedure licenses necessary for each surgical procedure.
LENSAR's focus on innovation doesn't stop at technology. They are dedicated to building a vibrant team of talented and motivated individuals who share their passion for making a significant impact on patients' lives. The company continues to push the boundaries of what's possible in refractive cataract surgery, ensuring that their technology remains at the cutting edge of medical advancements.
LENSAR (Nasdaq: LNSR) reported a 16% revenue increase for Q3 2021, totaling $8.3 million, driven by a 23% rise in procedure volumes compared to Q3 2020. Cash and cash equivalents stood at $32.3 million after $2.2 million in cash utilization for the quarter. The company anticipates a 510(k) filing for its ALLY™ Adaptive Cataract Treatment System in Q1 2022. However, the net loss for the quarter widened to $6.2 million, or ($0.65) per share. R&D expenses surged 59% to $3.2 million, primarily for the development of the ALLY system.
LENSAR, Inc. (NASDAQ: LNSR) will release its third quarter 2021 financial results on November 8, 2021, before market open. A conference call and webcast will follow at 8:30am ET on the same day to discuss these results and corporate highlights. LENSAR specializes in advanced femtosecond laser technologies for cataract treatment, aiming to improve visual outcomes for patients through its proprietary laser system.
LENSAR, Inc. (Nasdaq: LNSR) has announced that CEO Nick Curtis will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with the presentation available on-demand from 7:00 a.m. Eastern Time. The webcast can be accessed through the company's website and will remain available for one month following the event. LENSAR specializes in advanced femtosecond laser surgical solutions for cataracts, aiming to improve surgical outcomes through innovative technology.
LENSAR, a global medical technology leader in femtosecond laser surgical solutions for cataracts, announced CEO Nick Curtis will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET and can be accessed through the Company's website. LENSAR specializes in advanced laser systems designed to improve visual outcomes and efficiency in cataract surgery.
LENSAR, Inc. (Nasdaq: LNSR) reported significant financial growth for Q2 2021, achieving a 57% increase in total revenue to $7.9 million compared to Q2 2020, driven by a 70% rise in procedure volume. The company’s recurring revenue rose to 90%, up from 78% the previous year. Despite this growth, LENSAR recorded a net loss of $4.4 million, slightly improved from a loss of $4.5 million in Q2 2020. R&D expenses surged by 110% to $3 million, reflecting continued development of the ALLY system, expected to launch in 2022. The company maintained a cash position of $34.6 million.
LENSAR, Inc. (NASDAQ: LNSR) will release its second quarter 2021 financial results on August 5, 2021, before market open. A conference call and webcast will follow at 8:30 am ET on the same day to discuss the results and recent corporate highlights. LENSAR specializes in advanced femtosecond laser surgical solutions for cataract treatment, utilizing proprietary technologies aimed at enhancing surgical outcomes and efficiency.
LENSAR, Inc. (NASDAQ: LNSR) announced the acceptance of 12 abstracts showcasing its advanced femtosecond laser technology at the 2021 ASCRS Annual Meeting from July 23-27 in Las Vegas. The company will also demonstrate its next-gen ALLY™ Adaptive Cataract Treatment System, with a 510(k) application expected in Q1 2022 and a commercial launch planned for later that year. CEO Nick Curtis emphasized the significance of these presentations in validating LENSAR's innovations and improving patient outcomes in cataract surgeries.
LENSAR, a global medical technology company focused on femtosecond laser solutions for cataract treatment, announced that CEO Nick Curtis will present at the Oppenheimer MedTech, Tools, & Diagnostics Summit on May 26, 2021. The presentation will be available on-demand starting at 8:00 a.m. ET on the company's website and accessible for two weeks thereafter.
The LENSAR Laser System aims to enhance surgical outcomes with advanced imaging and efficient design, targeting cataracts and astigmatism management.
LENSAR, Inc. (LNSR) reported financial results for Q1 2021, with total revenues reaching $7.0 million, a 19.3% increase from $5.9 million in Q1 2020. This growth is attributed to enhanced sales of LENSAR Laser Systems and procedure licenses, particularly in the U.S. However, the net loss widened to $5.2 million ($0.56 per share) compared to $3.7 million in the previous year. The company anticipates launching its next-generation system, ALLY™, with a 510(k) filing expected in 2022. As of March 31, 2021, LENSAR held $35.9 million in cash, down from $40.6 million at the end of 2020.
LENSAR, Inc. (NASDAQ: LNSR) will release its first quarter 2021 financial results on May 5, 2021, prior to market opening. The company specializes in advanced femtosecond laser surgical solutions for cataracts and will host a conference call at 8:30 am ET on the same day to discuss these results and recent corporate highlights. Interested participants can join via telephone or access the live webcast on LENSAR's website. The company is committed to enhancing visual outcomes with its proprietary LENSAR Laser System.
FAQ
What is the current stock price of LENSAR (LNSR)?
What is the market cap of LENSAR (LNSR)?
What does LENSAR, Inc. specialize in?
What is the LENSAR Laser System?
What makes the LENSAR Laser System unique?
What is Augmented Reality™ in the context of LENSAR?
What is included in LENSAR's product portfolio?
What are the consumable components of the LENSAR Laser System?
What is the primary focus of LENSAR, Inc.?
How does LENSAR contribute to the surgical process?
How does LENSAR ensure the effectiveness of its technology?
What drives the success of LENSAR, Inc.?
